Briacell Therapeutics Corp BCTX

$4.26 +0.18 (4.41%)

Valuation

Market cap
36,148,000
Revenue TTM
$0
Net income TTM
$-26,310,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
39,783
Avg volume
323,008
Day's range
$4.01 – $4.33
Shares out
8,700,000
Stochastic %K
59%
Beta
1.10
Analysts
Strong Buy
Price target
$40.00

Price

Company profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator...

Show more

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 921 1810
Website
https://briacell.com
Address
Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

Latest news

Stocktwits

smallpower17 Sep 30, 3:17 PM
$OSTX $BCTX For my friends in OSTX and BCTX, you might also want to take a look at $SCYX It also has some exciting 2026 catalysts and a ton of upside.
0 replies
Manwiththeplan Sep 30, 2:04 PM
$BCTX Renmark Virtual Non-Deal Roadshow: TSX - BCT | NASDAQ - BCTX (ID 3074) https://share.google/QrWoiJfNbdIwHbQrD
1 replies
Biotechlineup Sep 30, 12:10 PM
$BCTX 4.06 pre market?? Here’s the institutions being lazy in the new world of AI. That’s my theory. No body listened , at least with a brain anyway at a little roadshow. AI are not listening, just waiting for the transcript being printed then in a nano second interpretation. Yesterday should be market breaking news and turned BCTX from a high risk gamble into a timely investment opportunity. This lag is your chance imo . 1) science, check 2) fundamentals, on 9/29 taking dilution off the table on interim results. Check 3) technical, I can go into great detail, let’s put it this way it all adds up to a pre super golden cross trigger. Check ,check , check!!
1 replies
BTC3030 Sep 30, 11:41 AM
$BCTX
0 replies
Biotechlineup Sep 30, 11:36 AM
$NVAX $BCTX $MRNA on my quest for the Holy Grail , everything coming together. An off shelf personalized cancer treatment that would be highly effective and also available cheaply worldwide wide that insurers would gladly pay for. Matrix m the power house adjuvant that will turn cold tumors hot. 2nd generation mRNA that will turn cold tumors hot like iOncologi and glioblastoma. Moderna neoantigen personalized vaccine with Merck going to fail miserably to a small micro micro micro cap BCTX which I ran across researching matrix m compatible oncolgy companies. Many bringing up multiple other companies that might be Moderna’s competitor. The direct competitor that targets the same patient population at a fraction of the cost is Bctx. That one just triggered my famous PRE Super Golden Cross technical signal. Moderna? An overpriced overhyped mRNA platform. Novavax? Anybody say 100 please.
0 replies
Biotechlineup Sep 30, 9:25 AM
$BCTX Simple biotech rules. 1) science 2)) fundamentals 3) Technical
0 replies
JediGreen Sep 30, 8:12 AM
$BCTX Pele (Hawaiian): Known as "She who shapes the sacred land," Pele lives in the Halemaʻumaʻu crater of the Kīlauea volcano. Legends say she creates new land with flowing lava and holds a powerful, unpredictable temper. 🌋 🙂 🌴 🌊
0 replies
Biotechlineup Sep 30, 12:59 AM
$BCTX The Phase 2 study patients who were DHT+ lived more than double the length of time compared to those who were DHT - , 11.3 months vs 4.7 months By saying this is happening in the majority of the current Phase 3 patients, management is heavily implying that most patients on the active drug arm are successfully generating the protective immune response required to extend their lives. Control Arm is of course DHT- . Unfortunately for the control arm is not doing well. That’s 2+2 speculation if management stated they are on track for Dec then the majority must be in the control arm and therefore high likelihood of a .6 HR? https://briacell.com/briacell-presents-outstanding-phase-2-survival-promising-phase-3-clinical-data-at-sabcs-2025/ <>Positive Delayed Type Hypersensitivity (DTH) may be key predictor of clinical benefit as median overall survival (OS) was significantly (P=0.0001) higher in patients who were DTH+ (11.3 months) vs those who were DTH- (4.7 months).>>
0 replies